OncoMatch

OncoMatch/Clinical Trials/Leukemia — Acute Myeloid (AML)

Leukemia — Acute Myeloid (AML) Clinical Trials

Recruiting trials·Updated daily from ClinicalTrials.gov

OncoMatch filters Leukemia — Acute Myeloid (AML) trials by the molecular markers that determine eligibility — FLT3, IDH1, IDH2, NPM1, and more. Enter your biomarker results to see only the trials you may qualify for.

Compare eligibility criteria
Biomarker panel

Biomarkers tested in Leukemia — Acute Myeloid (AML) trials

These are the molecular markers most commonly required or evaluated in Leukemia — Acute Myeloid (AML) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.

FLT3IDH1IDH2NPM1TP53ASXL1KMT2A (MLL)RUNX1CEBPAKITNRASKRASDNMT3ATET2

How OncoMatch finds Leukemia — Acute Myeloid (AML) trials for you

01

AI reads the protocol

Every Leukemia — Acute Myeloid (AML) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.

02

You enter your results

Select Leukemia — Acute Myeloid (AML) and mark your biomarker results — FLT3, IDH1, IDH2 — as positive, negative, or not tested. Your data never leaves your device.

03

See only relevant trials

Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.

Find Leukemia — Acute Myeloid (AML) trials →